Genocea Biosciences (GNCA) Posts Smaller-than-Expected Q2 Loss

Genocea Biosciences (NASDAQ: GNCA) reported Q2 EPS of ($0.05), $0.08 better than the analyst estimate of ($0.13).

As of June 30, 2018, cash and cash equivalents were $44.2 million compared to $12.3 million as of December 31, 2017.

“We’re proud to announce that we have just initiated the Phase 1/2a clinical trial for GEN-009, our lead neoantigen vaccine candidate,” said Chip Clark, president and chief executive officer of Genocea. “We continue to expect to report the early immunogenicity data from the first patient cohort in the first half of 2019 and remain hopeful these data will provide additional evidence that our ATLAS platform identifies what we call true neoantigens, which we expect to enable more immunogenic and, ultimately, more efficacious vaccines.” Mr. Clark concluded, “This is an exciting time at Genocea, as we believe we are well positioned to help transform cancer treatment.”

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• ITG (ITG) Tops Q2 EPS by 1c
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c